Dr. Anthony J. Jaslowski, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Loyola University of Chicago, Stritch School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 388
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Loyola University of Chicago, Stritch School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WI license 29926
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Vincent Hospital Green Bay, WI
- Ascension Ne Wisconsin - St Elizabeth Campus Appleton, WI
- Door County Medical Center Sturgeon Bay, WI
- Osf St Francis Hospital and Medical Group Escanaba, MI
- Schoolcraft Memorial Hospital Manistique, MI
Medical groups
- Osf Multi-Specialty Group (2,114 clinicians)
- St Vincent Hospital-Hospital Sisters-Third Order of St Francis (603 clinicians)
- Ascension Ne Wisconsin, Inc (19 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 388
- Services billed
- 727
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 446 | 251 |
| Established patient office or other outpatient visit, 40-54 minutes | 84 | 68 |
| New patient office or other outpatient visit, 45-59 minutes | 66 | 66 |
| Established patient office or other outpatient visit, 20-29 minutes | 28 | 22 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 26 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Hospital discharge day management, more than 30 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamoxifen Citrate Other prescribers in Green Bay, WI | 116 |
| Ondansetron Hcl Other prescribers in Green Bay, WI | 102 |
| Prednisone Other prescribers in Green Bay, WI | 67 |
| Anastrozole Other prescribers in Green Bay, WI | 62 |
| Abiraterone Acetate | 47 |
| Acyclovir Other prescribers in Green Bay, WI | 43 |
| Eliquis (apixaban) Other prescribers in Green Bay, WI | 42 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Green Bay, WI | 41 |
| Oxycodone Hcl Other prescribers in Green Bay, WI | 40 |
| Olanzapine Other prescribers in Green Bay, WI | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $292 in total to this clinician.
| Genmab U.S., Inc. | $96.72 |
|---|---|
| Adc Therapeutics America, Inc. | $90.66 |
| Sobi, Inc | $88.56 |
| Janssen Scientific Affairs, LLC | $15.71 |
| Food and Beverage | $292 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $64,181 in research payments for these studies, mostly to the institutions running them.
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06577441 - A Phase 3 Clinical Trial of Pembrolizumab MK-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC - Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
AbbVie Inc. · Active, not recruiting · NCT04468984 - A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects KEYNOTE-407
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.